# GILEAD SCIENCES, INC. (GILD) FY2024 Q3 P&L / Income Statement - Company: GILEAD SCIENCES, INC. (GILD) - Period: 2024-07-01 to 2024-09-30 - Filing: Q3 FY2024 10-Q, filed 2024-11-12, accession number 0000882095-24-000028 - Page: https://plicit.ai/financials/gild/fy2024-q3-income-statement - Chart image: https://plicit.ai/charts/gild-fy2024-q3-income-statement-sankey.png ## Chart details: Revenue by Product and Service by Geography Income statement for 2024-07-01 through 2024-09-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Total revenues**: 7,545,000,000 US dollars - **Cost of goods sold**: 1,574,000,000 US dollars - **Gross profit (calculated)**: 5,971,000,000 US dollars - **Operating expenses (calculated)**: 5,083,000,000 US dollars - **Operating income (loss)**: 888,000,000 US dollars - **Other income (expense), net (calculated)**: 68,000,000 US dollars - **Income (loss) before income taxes**: 956,000,000 US dollars - **Income tax (benefit) expense**: negative 297,000,000 US dollars - **Net income (loss)**: 1,253,000,000 US dollars - **Tecartus - UNITED STATES**: 63,000,000 US dollars - **Tecartus - Rest of World**: 6,000,000 US dollars - **Tecartus - Europe**: 29,000,000 US dollars - **Total Cell Therapy - UNITED STATES**: 208,000,000 US dollars - **Total Cell Therapy - Rest of World**: 66,000,000 US dollars - **Total Cell Therapy - Europe**: 211,000,000 US dollars - **Yescarta - UNITED STATES**: 145,000,000 US dollars - **Yescarta - Rest of World**: 60,000,000 US dollars - **Yescarta - Europe**: 182,000,000 US dollars - **Total HIV - UNITED STATES**: 4,161,000,000 US dollars - **Total HIV - Rest of World**: 342,000,000 US dollars - **Total HIV - Europe**: 570,000,000 US dollars - **Biktarvy - UNITED STATES**: 2,826,000,000 US dollars - **Biktarvy - Rest of World**: 272,000,000 US dollars - **Biktarvy - Europe**: 375,000,000 US dollars - **Descovy - UNITED STATES**: 534,000,000 US dollars - **Descovy - Rest of World**: 28,000,000 US dollars - **Descovy - Europe**: 24,000,000 US dollars - **Genvoya - UNITED STATES**: 384,000,000 US dollars - **Genvoya - Rest of World**: 21,000,000 US dollars - **Genvoya - Europe**: 44,000,000 US dollars - **Odefsey - UNITED STATES**: 248,000,000 US dollars - **Odefsey - Rest of World**: 9,000,000 US dollars - **Odefsey - Europe**: 69,000,000 US dollars - **Other HIV - UNITED STATES**: 65,000,000 US dollars - **Other HIV - Rest of World**: 9,000,000 US dollars - **Other HIV - Europe**: 26,000,000 US dollars - **Symtuza - Revenue share - UNITED STATES**: 103,000,000 US dollars - **Symtuza - Revenue share - Rest of World**: 3,000,000 US dollars - **Symtuza - Revenue share - Europe**: 33,000,000 US dollars - **Total Liver Disease - UNITED STATES**: 393,000,000 US dollars - **Total Liver Disease - Rest of World**: 207,000,000 US dollars - **Total Liver Disease - Europe**: 132,000,000 US dollars - **Other Liver Disease - UNITED STATES**: 45,000,000 US dollars - **Other Liver Disease - Rest of World**: 17,000,000 US dollars - **Other Liver Disease - Europe**: 54,000,000 US dollars - **Sofosbuvir/Velpatasvir - UNITED STATES**: 222,000,000 US dollars - **Sofosbuvir/Velpatasvir - Rest of World**: 96,000,000 US dollars - **Sofosbuvir/Velpatasvir - Europe**: 67,000,000 US dollars - **Vemlidy - UNITED STATES**: 126,000,000 US dollars - **Vemlidy - Rest of World**: 95,000,000 US dollars - **Vemlidy - Europe**: 11,000,000 US dollars - **Total Oncology - UNITED STATES**: 433,000,000 US dollars - **Total Oncology - Rest of World**: 92,000,000 US dollars - **Total Oncology - Europe**: 291,000,000 US dollars - **AmBisome - UNITED STATES**: 6,000,000 US dollars - **AmBisome - Rest of World**: 52,000,000 US dollars - **AmBisome - Europe**: 71,000,000 US dollars - **Other - UNITED STATES**: 47,000,000 US dollars - **Other - Rest of World**: 16,000,000 US dollars - **Other - Europe**: 8,000,000 US dollars - **Total Other - UNITED STATES**: 53,000,000 US dollars - **Total Other - Rest of World**: 68,000,000 US dollars - **Total Other - Europe**: 80,000,000 US dollars - **Royalty, contract and other revenues - UNITED STATES**: 17,000,000 US dollars - **Royalty, contract and other revenues - Rest of World**: 1,000,000 US dollars - **Royalty, contract and other revenues - Europe**: 13,000,000 US dollars - **Trodelvy - UNITED STATES**: 226,000,000 US dollars - **Trodelvy - Rest of World**: 26,000,000 US dollars - **Trodelvy - Europe**: 80,000,000 US dollars - **Veklury - UNITED STATES**: 393,000,000 US dollars - **Veklury - Rest of World**: 219,000,000 US dollars - **Veklury - Europe**: 81,000,000 US dollars - **Product sales - UNITED STATES**: 5,433,000,000 US dollars - **Product sales - Rest of World**: 928,000,000 US dollars - **Product sales - Europe**: 1,154,000,000 US dollars - **Selling, general and administrative expenses**: 1,433,000,000 US dollars - **Acquired in-process research and development expenses**: 505,000,000 US dollars - **Research and development expenses**: 1,395,000,000 US dollars - **In-process research and development impairment**: 1,750,000,000 US dollars - **Revenue before reconciliation (calculated)**: 22,369,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation. - **Components above reported revenue (calculated)**: negative 14,824,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item. ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. - Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue. ## Chart details: Revenue by Product and Service (16 categories) - Page: https://plicit.ai/financials/gild/fy2024-q3-income-statement/revenue-by-product-and-service-16-categories - Chart image: https://plicit.ai/charts/gild-fy2024-q3-revenue-by-product-and-service-16-categories-sankey.png Income statement for 2024-07-01 through 2024-09-30. View: Product and service (16 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Total revenues**: 7,545,000,000 US dollars - **Cost of goods sold**: 1,574,000,000 US dollars - **Gross profit (calculated)**: 5,971,000,000 US dollars - **Operating expenses (calculated)**: 5,083,000,000 US dollars - **Operating income (loss)**: 888,000,000 US dollars - **Other income (expense), net (calculated)**: 68,000,000 US dollars - **Income (loss) before income taxes**: 956,000,000 US dollars - **Income tax (benefit) expense**: negative 297,000,000 US dollars - **Net income (loss)**: 1,253,000,000 US dollars - **Tecartus**: 98,000,000 US dollars - **Yescarta**: 387,000,000 US dollars - **Biktarvy**: 3,472,000,000 US dollars - **Descovy**: 586,000,000 US dollars - **Genvoya**: 449,000,000 US dollars - **Odefsey**: 326,000,000 US dollars - **Symtuza - Revenue share**: 139,000,000 US dollars - **Other HIV**: 100,000,000 US dollars - **Sofosbuvir/Velpatasvir**: 385,000,000 US dollars - **Vemlidy**: 232,000,000 US dollars - **Other Liver Disease**: 116,000,000 US dollars - **Trodelvy**: 332,000,000 US dollars - **AmBisome**: 130,000,000 US dollars - **Other**: 71,000,000 US dollars - **Royalty, contract and other revenues**: 30,000,000 US dollars - **Veklury**: 692,000,000 US dollars - **Selling, general and administrative expenses**: 1,433,000,000 US dollars - **Acquired in-process research and development expenses**: 505,000,000 US dollars - **Research and development expenses**: 1,395,000,000 US dollars - **In-process research and development impairment**: 1,750,000,000 US dollars ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. ## Chart details: Revenue by Product and Service (2 categories) - Page: https://plicit.ai/financials/gild/fy2024-q3-income-statement/revenue-by-product-and-service-2-categories - Chart image: https://plicit.ai/charts/gild-fy2024-q3-revenue-by-product-and-service-2-categories-sankey.png Income statement for 2024-07-01 through 2024-09-30. View: Product and service (2 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Total revenues**: 7,545,000,000 US dollars - **Cost of goods sold**: 1,574,000,000 US dollars - **Gross profit (calculated)**: 5,971,000,000 US dollars - **Operating expenses (calculated)**: 5,083,000,000 US dollars - **Operating income (loss)**: 888,000,000 US dollars - **Other income (expense), net (calculated)**: 68,000,000 US dollars - **Income (loss) before income taxes**: 956,000,000 US dollars - **Income tax (benefit) expense**: negative 297,000,000 US dollars - **Net income (loss)**: 1,253,000,000 US dollars - **Product sales**: 7,515,000,000 US dollars - **Royalty, contract and other revenues**: 30,000,000 US dollars - **Selling, general and administrative expenses**: 1,433,000,000 US dollars - **Acquired in-process research and development expenses**: 505,000,000 US dollars - **Research and development expenses**: 1,395,000,000 US dollars - **In-process research and development impairment**: 1,750,000,000 US dollars ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. ## Chart details: Revenue by Geography - Page: https://plicit.ai/financials/gild/fy2024-q3-income-statement/revenue-by-geography - Chart image: https://plicit.ai/charts/gild-fy2024-q3-revenue-by-geography-sankey.png Income statement for 2024-07-01 through 2024-09-30. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Total revenues**: 7,545,000,000 US dollars - **Cost of goods sold**: 1,574,000,000 US dollars - **Gross profit (calculated)**: 5,971,000,000 US dollars - **Operating expenses (calculated)**: 5,083,000,000 US dollars - **Operating income (loss)**: 888,000,000 US dollars - **Other income (expense), net (calculated)**: 68,000,000 US dollars - **Income (loss) before income taxes**: 956,000,000 US dollars - **Income tax (benefit) expense**: negative 297,000,000 US dollars - **Net income (loss)**: 1,253,000,000 US dollars - **UNITED STATES**: 5,450,000,000 US dollars - **Europe**: 1,167,000,000 US dollars - **Rest of World**: 929,000,000 US dollars - **Selling, general and administrative expenses**: 1,433,000,000 US dollars - **Acquired in-process research and development expenses**: 505,000,000 US dollars - **Research and development expenses**: 1,395,000,000 US dollars - **In-process research and development impairment**: 1,750,000,000 US dollars - **Revenue before reconciliation (calculated)**: 7,546,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation. - **Components above reported revenue (calculated)**: negative 1,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item. ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. - Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.